ProQR Therapeutics N.V.(PRQR)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $1.4M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
PRQR Stock Analysis & AI Quality Score
AI stock analysis and institutional research for ProQR Therapeutics N.V. (PRQR), a Healthcare sector company. PRQR is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $1.4m in revenue. Top institutional holders of PRQR by reported 13-F value include ADAGE CAPITAL PARTNERS GP, L.L.C., Privium Fund Management B.V., abrdn plc, based on the most recent SEC filings. PRQR trades on the Nasdaq exchange and files with the SEC under CIK 1612940. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PRQR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ProQR Therapeutics N.V. directly from SEC EDGAR.
Get alerted when PRQR's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for ProQR Therapeutics N.V. including:
Top Institutional Holders of PRQR
ADAGE CAPITAL PARTNERS GP, L.L.C.
$10.1M6,253,467 shPrivium Fund Management B.V.
$8.9M5,467,149 shabrdn plc
$5.4M3,316,965 shAffinity Asset Advisors, LLC
$4.0M2,454,278 shSio Capital Management, LLC
$3.2M1,954,715 shDAFNA Capital Management LLC
$2.5M1,567,561 shKynam Capital Management, LP
$2.5M1,566,317 shIkarian Capital, LLC
$2.4M1,492,229 shMORGAN STANLEY
$2.1M1,299,775 shPLATINUM INVESTMENT MANAGEMENT LTD
$2.0M1,235,514 sh
| Fund | Value | Shares |
|---|---|---|
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $10.1M | 6,253,467 |
| Privium Fund Management B.V. | $8.9M | 5,467,149 |
| abrdn plc | $5.4M | 3,316,965 |
| Affinity Asset Advisors, LLC | $4.0M | 2,454,278 |
| Sio Capital Management, LLC | $3.2M | 1,954,715 |
| DAFNA Capital Management LLC | $2.5M | 1,567,561 |
| Kynam Capital Management, LP | $2.5M | 1,566,317 |
| Ikarian Capital, LLC | $2.4M | 1,492,229 |
| MORGAN STANLEY | $2.1M | 1,299,775 |
| PLATINUM INVESTMENT MANAGEMENT LTD | $2.0M | 1,235,514 |
More Healthcare Companies
View all Healthcare →Put PRQR on your watchlist
Track score changes the day ProQR Therapeutics N.V. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is PRQR a good stock to buy?
13F Pro's AI-powered analysis of ProQR Therapeutics N.V. (PRQR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PRQR are available on the PRQR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own PRQR?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PRQR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ProQR Therapeutics N.V.'s investment landscape.